Last updated: March 2026
Boldenone undecylenate (Equipoise) was originally developed as a veterinary injectable for horses. Its 1,2-double bond modification of testosterone produces mild aromatization, strong red blood cell stimulation, and appetite increase. This educational reference covers its pharmacology, effects, cardiovascular risks, and the extremely long detection window.
Boldenone is testosterone with an added 1,2-double bond in the A-ring. This seemingly small change profoundly alters its pharmacology — reducing androgenic and estrogenic activity while enhancing its erythropoietic (RBC-stimulating) effects.
Boldenone strongly stimulates erythropoietin (EPO) production in the kidneys, driving red blood cell production. This raises hematocrit, hemoglobin, and oxygen-carrying capacity — producing endurance benefits but also significantly increasing blood viscosity. Hematocrit above 52–54% dramatically increases thrombosis, stroke, and cardiac event risk. Regular hematocrit monitoring is essential harm reduction.
Boldenone is uniquely potent for appetite stimulation among AAS — the mechanism is not fully characterized but likely involves central androgen receptor signaling and ghrelin modulation. This makes it useful for bulking phases where caloric surplus is desired but can complicate cutting protocols. Users report dramatically increased hunger within weeks of initiating use.
The 1,2-double bond slows aromatase conversion to estradiol. Boldenone aromatizes at roughly 50% the rate of testosterone — producing moderate but manageable estrogenic activity. Water retention and gynecomastia risk are lower than testosterone or Dianabol. An aromatase inhibitor may still be needed at higher doses or in estrogen-sensitive individuals.
The undecylenate ester gives boldenone an approximate 14-day half-life in vivo. This extends its active life for weekly or bi-weekly dosing convenience — but means it accumulates slowly (full effect not felt for 4–6 weeks) and detection windows extend to 4–5 months in urine testing. WADA long-term metabolites may be detectable for even longer periods.
Data from pharmacological studies, veterinary research, and clinical literature on boldenone undecylenate.
Hematocrit monitoring is critical harm reduction for Equipoise use — elevated RBC viscosity is the primary serious risk.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and harm reduction purposes only. It is not medical advice. Boldenone undecylenate (Equipoise) is a Schedule III controlled substance in the United States with no approved human medical use. It is banned by WADA and all major sports organizations. Use carries significant health risks including thrombosis, cardiovascular disease, and hormonal disruption. Hematocrit elevation from boldenone use can cause serious, life-threatening clotting events. Consult a qualified physician before making any decisions regarding hormone use. MeetPeptide does not endorse or encourage the use of controlled substances.